Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Mounjaro

NHS staffer now forced to work extra shifts to cover cost of Mounjaro

Carly Stokes dropped six stone in a year using the weight loss jab

The Independent UK

‘I lost more than 2 stone on Mounjaro - but my hair started to fall out’

Rhiannon Anne Griffiths-Bowen says the weight-loss benefits of taking Mounjaro outweighed the issue of hair loss

The Independent UK

‘Gutted’: UK users of weight loss jab Mounjaro devastated by planned price hike

People using the jab reported positive results, but many say the increased cost will be prohibitively expensive, and they expect to put the weight back on when they stop

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Mounjaro users in UK warned against bulk buying before autumn price rise

Cost may increase as much as 170% from September, but patients warned against a quick switch to Wegovy

The Guardian - UK

Voices: Pricing people out of using Mounjaro would be bad news for the NHS

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous – impact on Britain’s pharmacies and patients, writes Leyla Hannbeck, CEO of the Independent Pharmacies Association

The Independent UK

Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%

The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS).

Euronews

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

Benzinga

Weight-loss jab Mounjaro helps people shed much more weight than rival – study

Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and therefore less hungry.

The Independent UK

Meghan Trainor reveals husband is also using Mounjaro after he gained some sympathy ‘pregnancy weight’

The ‘Dear Future Husband’ singer revealed she was taking Mounjaro earlier this month

The Independent UK

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

The Independent UK

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart

Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic

Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The 'Transformative' Eli Lilly Drug That Could Top $25 Billion In Annual Sales

Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the National Health Service

34 stories

Mounjaro

15 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.